French pharmaceutical group Servier is positioning India as a key global export platform for complex therapies, announcing an annual investment of €15 million to build and scale GATINN (Global Accelerator for Technologies and Innovation in New-generation Nutraceuticals). According to reports from Mint, this platform will focus on developing and exporting single-pill combinations (SPCs) for cardiometabolic and venous diseases to emerging markets across Southeast Asia, Latin America, West Asia, and Africa. Based on current products in scope, the company estimates the export platform could generate up to €500 million in revenue after 2030, subject to regulatory approvals, registrations and market uptake. The first product is expected to be shipped out by October 2027.
GATINN represents Servier's first such platform globally and will function as a single coordination centre, integrating product development, manufacturing, supply chain, and quality oversight for export markets. As reported by Mint, manufacturing will be carried out through selected Indian contract development and manufacturing organisations (CDMOs), while Servier will retain control over quality-critical components and processes through its global quality systems. India's domestic market will continue to be served through Servier India's existing portfolio, with GATINN designed as a purely export-focused platform. The company plans to export single-pill combinations to countries in regions such as Latin America, Asia, and Africa, where the burden of cardiometabolic diseases is high.
Servier has already invested around €15 million to establish GATINN and expects to deploy roughly €15 million per year over the next few years, depending on the number of projects that progress through development. According to Mint, investments will be directed towards formulation and product development, bioequivalence and regulatory studies, onboarding and auditing of CDMO partners, and scaling up export manufacturing. The platform is expected to have around five products in development by the end of 2026, with approximately one new combination added each year till 2030. While the development and manufacturing will happen locally, the APIs will be imported from Servier's production facilities.
To manage quality and execution risks, the company has implemented US Food and Drug Administration- and European Medicines Agency-aligned quality systems, including a centralised outsourcing committee with veto powers, direct reporting lines to Servier's global quality leadership, and on-site audits of CDMO partners. As reported by Mint, Servier's managing director Bradley Lloyd highlighted India's technological advantage, stating "India has a real technological advantage in its ability to find innovative ways to put molecules together or to evolve formulations in order to achieve either single pill combinations or new ways to deliver the active substance." The idea behind developing single-pill combinations for cardiovascular and metabolic diseases addresses the problem of adherence to multiple pills, particularly for chronic conditions with growing incidence rates globally.
This move marks a significant shift in Servier's approach to India — from primarily a domestic market and sourcing base to a coordinated hub for late-stage development and exports. According to Mint, Aurelien Breton, managing director of Servier India, stated "India was a market for Servier, now India is becoming a hub for Servier." The investment is less about near-term returns and more about building a durable, scalable export engine anchored in India over the next decade. The strategy aligns with Servier's broader focus on sharpening its focus on cardiometabolic and venous diseases while expanding its footprint in emerging markets, where disease burden is high and long-term treatment adherence remains a challenge. Servier is France's second-largest pharma company after Sanofi, and ranks 35 in the global pecking order, posting revenues of €6.9 billion in the 2024-25 financial year.
